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Abstract
Background: The family of 4 related protease-activated receptors (PAR-1, 2, 3 & 4) expressed by mammalian cells
allow to sense for and react to extracellular proteolytic activity. Since major human bacterial pathogens secret a wide
array of protease(-s) we investigated whether they interfere with human PAR function.
Methodology/Principal Findings: Supernatants from cultures of major human bacterial pathogens were assayed
for the presence of protease(-s) capable to cleave overexpressed human PAR-1, 2, 3 and 4 reporter constructs.
Group A streptococcus (GAS) was found to secret a PAR-1-cleaving protease. Experiments involving genetical and
pharmacological gain and loss of function identified streptococcal pyrogenic exotoxin B SpeB as the protease
responsible. On the host’s side analysis of overexpressed PAR-1 carrying alanine substitutions and deletions showed
the amino acid residue leucine44 on PAR-1’s extracellular N-terminus to be the only cleavage site. Complementary
studies on endogenously expressed PAR-1 using PAR-1 blocking antibodies further supported our conclusion.
Through PAR-1 cleavage SpeB efficiently blunted thrombin-induced induction of the ERK-pathway in endothelial cells
and prevented platelets aggregation in response to thrombin.
Conclusions/Significance: Our results identify a novel function of the streptococcal virulence factor SpeB. By
cleaving human PAR-1 at the N-terminal amino acid residue leucine44 SpeB rendered endothelial cells unresponsive
to thrombin and prevented human platelets from thrombin-induced aggregation. These results suggest that by
blunting PAR-1 signaling, SpeB modulates various innate host responses directed against invasive GAS potentially
helping the invasive bacteria to escape. This may allow to tailor additional treatments in the future since upon
invasion of the blood stream endothelial cells as well as platelets and mononuclear cells respond to PAR-1 agonists
aiming to prevent further bacterial dissemination.
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Introduction
Group A Streptococcus (GAS) is one of the top ten
pathogens causing infection-related deaths world-wide and is
responsible for around 0.5 million deaths annually [1]. GAS has
evolved a variety of virulence factors facilitating efficient host
colonization and invasion [2].
GAS makes use of the host’s clotting network to increase its
virulence. Plasminogen activation and recruitment by GAS was
for example found to promote the pathogen’s capability to
overcome the host’s barriers and to facilitate blood stream
infection [3]. Also the host’s capacity to form fibrin clots is
crucial to contain bacterial spread after blood stream invasion
[4,5]. On the other hand increased clot formation was shown to
boost bacterial dissemination [6]. Recently, studies exploring
the bacteria-host interaction from the host’s side showed that a
clotting enzyme receptor, the protease activated receptor
(PAR)-1, impairs survival in a mouse pneumococcal
pneumonia model [5] further underlining the interplay between
bacteria and the host’s clotting components in the modulation
of bacterial virulence.
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e81298
PARs consist of a family of 4 highly related G protein-
coupled receptors, abundantly expressed on almost all
mammalian cells [7]. PARs allow cells to sense for extracellular
enzymatic activity [8] through a unique proteolytic receptor
activation mechanism. PAR molecules contain hidden
activation ligands within their extracellular N-terminus.
Proteolytic removal of N-terminal peptides expose neo-amino
N-termini that serve as tethered ligands either activating the
same receptor molecule [9] or an adjacent PAR molecule [10],
thereby initiating transmembrane signaling. Recently PAR-1
was shown to carry several cleavage sites which uncover
various signalling-competent tethered ligands causing ligand-
specific biological effects [11–13].
The impact of PAR-1 activation by mammalian proteases
and the resulting effects on systemic inflammation has been
extensively studied [14–19]. This receptor was found to have
important effects on regulating and maintaining the vascular
barrier integrity [18], cytokine secretion [20], apoptosis [11,14]
and cell proliferation [21]. However studies on how the initiators
of systemic inflammation such as bacterial pathogens impact
PAR-1 are scarce [22]. So far it was found that the pathogen
Porphyromonas gingivalis causing local infections such as
periodonitis promotes platelet activation [23] and that
Pseudomonas aeruguinosa activates PAR-1 and mediates
thrombin-like biological effects [24]. However, to our
knowledge, major human Gram positive bacterial pathogens
responsible for the majority of systemic bacterial infections and
consecutive systemic inflammation have not yet been reported
to affect PAR-1.
Herein we studied whether the human bacterial pathogen
GAS responsible for up to 0.66 million yearly systemic
infections worldwide [1], affects PAR-1. We found that the GAS
secreted cysteine protease streptococcal pyrogenic exotoxin B
(SpeB) efficiently cleaved PAR-1. We identified its specific
cleavage site and studied biological downstream effects. We
showed that SpeB attenuated extracellular-signal-regulated
kinase (ERK) phosphorylation and rendered PAR-1
unresponsive to thrombin and thereby blunted platelet
activation.
Results
Specific cleavage of PAR-1 by group A streptococcal
supernatants
In order to test whether GAS secretes proteases capable of
cleaving PARs we relied on a cleavage reporter system we had
previously used to characterize human serine proteases
[11,25]. In brief all four human PARs encoding mRNAs were
cloned and the signal sequences were replaced by stop codon-
truncated mRNA encoding for secreted alkaline phosphatase
(AP). The resulting chimeric PARs carrying a N-terminal AP
were successfully expressed in transiently transfected 293T
cells and used to screen whether supernatants of relevant
human pathogens such as GAS specifically cleaved one of the
4 human PARs. Among the bacterial supernatants screened
we identified GAS to efficiently and selectively cleave PAR-1
(Figure 1A) and confirmed earlier studies showing that P.
aeruginosa cleaves PAR 1, 2, 4 [24,26] and less efficiently
PAR-3 (Figure 1A-D).
PAR-1 cleavage by streptococcal SpeB
To identify the streptococcal protease responsible for PAR-1
cleavage we took a stepwise approach. We first used specific
protease inhibitors to identify the protease family and found
that only the cysteine protease inhibitor E64 blunted PAR-1
cleavage (Figure 2A) consistent with a streptococcal cysteine
protease cleaving PAR-1. GAS protease expression is modified
according to the growth phase [27]. To narrow down which
streptococcal cysteine protease cleaved PAR-1 we thus
compared supernatants from exponential and stationary growth
phase GAS cultures. We found that the protease was
expressed during the stationary growth phase (Figure 2B). Late
growth phase enzyme expression together with a zymography
(not shown) showing strong proteolytic activity under reducing
conditions at around 42 kDa suggested the streptococcal
pyrogenic exotoxin B (SpeB) to be the causal protease.
Consistent with our hypothesis we detected functional SpeB in
supernatants from stationary phase cultures (Figure 2C) using
the chromogenic cysteine protease substrate Bz-Pro-Phe-Arg-
Nan [28]. To test whether SpeB is required and sufficient for
PAR-1 cleavage we analysed supernatants from GAS
expressing SpeB (GAS wildtype) or the isogenic SpeB-deficient
GAS (GAS∆speB) in the absence and presence of
exogenously added commercial SpeB. PAR-1 was found to be
always cleaved when functional SpeB was present consistent
with SpeB being responsible for PAR-1 cleavage (Figure 2D).
PAR-1 cleavage restricted to SpeB-expressing clinical
isolates
In up to 40% of invasive GAS, the expression of SpeB [3] is
strongly reduced due to either point mutation(-s) or deletions
within the main GAS two component regulatory system CovR/S
or mutations within ropB (also known as Rgg) [29]. Therefore
we tested the association between SpeB expression and
PAR-1 cleavage in clinical isolates. In addition to the well
characterized invasive GAS M1T1 and M49 strains we further
tested clinical GAS isolated from patients suffering from
invasive GAS infections (Table S1). We tested whether all the
GAS strains expressed SpeB and whether they cleaved
PAR-1. Among the clinical isolates tested a large proportion
(62.5 %; not including the reference strains) cleaved PAR-1
(Figure 3A). All strains that cleaved PAR-1 also secreted
functional SpeB (Figure 3B).
Cleavage efficiency of SpeB
We next addressed how efficiently SpeB cleaved PAR-1.
Since protein-protein interactions, such as the direct binding of
thrombin to PAR-1 [30] and the availability of co-receptors
might influence PAR-1 cleavage, we expanded our studies and
used cell surface expressed AP-PAR-1. We compared SpeB
and thrombin PAR-1 cleavage efficiency and found the latter to
be around 9 times more efficient (Figure 4).
Streptococcal SpeB Cleaves PAR-1
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Cleavage of endogenously expressed PAR-1 by SpeB
Cleavage of PAR-1’s N-terminus either renders the receptor
dysfunctional [31] or induces transmembrane signaling
dependent on the cleavage site. Cleavage can in fact occur at
several sites and uncover various neo-N-terminal tethered
ligands that mediate a variety of divergent biological effects
[11–13]. We thus investigated whether SpeB cleaved at a
single specific amino residue and its exact cleavage location.
We first used monoclonal anti-PAR-1 antibodies and tested
whether streptococcal-derived or commercial SpeB removed
the anti-PAR-1 epitope from endogenously endothelial cell
surface-expressed PAR-1. Anti-PAR-1 ATAP2 binds to the
thrombin-generated tethered ligand whereas WEDE15 binds C-
terminal of the hirudin-like domain (Figure 5A). We used
ATAP2 and WEDE15 to test by cell surface ELISA [32] whether
SpeB can remove the ATAP2 or WEDE15 epitope from the N-
terminus of endogenously EA.hy926 endothelial cell expressed
PAR-1. Both streptococcal-derived and commercial SpeB
removed ATAP2 epitopes consistent with cleavage within or C-
terminal of the ATAP2 epitope [11,32]. In contrast binding of
WEDE15 was only weakly affected (Figure 5B). Taken together
these data are consistent with SpeB cleaving between R46 and
W56. As a complementary approach we used the same
antibodies in our cleavage reporting system and tested whether
the presence of either antibody interfered with SpeB cleavage.
ATAP2 but not WEDE15 prevented cleavage of both
Figure 1.  Screening of bacterial supernatants for cleaving PAR reporter constructs.  293T cells transiently over-expressing
alkaline phosphatase tagged PAR-1 (A), PAR-2 (B); PAR-3 (C) or PAR-4 (D) were incubated with bacterial supernatants of GAS as
well as other pathogenic bacteria P1-P5 (P1 representing Enterococcus cloacae, P2 Pseudomonas aeruginosa, P3 Klebsiella
pneumonia, P4 Burkholderia cepacia complex, and P5 Methicillin-resistant Staphylococcus aureus). Positive controls used for
PAR-1, 3 and 4 was thrombin (IIa) and for PAR-2 trypsin. Released alkaline phosphatase activity was quantified. Representative
experiment of 3 with N=9, data presented as mean +/- SEM.
doi: 10.1371/journal.pone.0081298.g001
Streptococcal SpeB Cleaves PAR-1
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streptococcal-derived and commercial SpeB providing
complementary evidence that SpeB cleaved in proximity of the
ATAP2 epitope (Figure 5C). In addition and most importantly,
cleavage blocking also ruled out that SpeB cleaved AP
somewhere between the protease domain and the linkage to
PAR-1.
Specific cleavage at L44-45 by SpeB
To further corroborate our data and to generate additional
lines of evidence we constructed a chimeric AP-PAR-1
molecule with a FLAG-tag at the fusion site homologous to the
one published previously [33]. Thrombin and streptococcal-
derived protease removed the FLAG-tag together with AP
Figure 2.  Streptococcal protease responsible for PAR-1 cleavage.  (A) GAS supernatants pre-incubated with either the
metalloprotease inhibitor EDTA, the serine protein inhibitors PMSF and benzamidine (BAM), the cysteine protease inhibitor E64 or
buffer were added onto 293T cells transiently over-expressing alkaline phosphatase-tagged PAR-1. Released alkaline phosphatase
activity was quantified in the supernatants. (B) Cells as described in (A) were incubated with supernatants from exponential and
stationary GAS to analyse their efficiency in cleaving AP-PAR-1 reporter constructs. (C) SpeB proteolytic activity was analysed by
Bz-Pro-Phe-Arg-Nan cleavage in the exponential and stationary cultures GAS samples used in (B). Commercial SpeB (13.3 µg/ml)
served as a positive control. (D) AP-PAR-1 reporter constructs were incubated with overnight cultures of non pre-treated wild type
GAS, GAS preincubated with cysteine protease inhibitor E64 or the isogenic speB deficient GAS (GAS∆speB). In addition
supernatants from GAS∆speB were complemented with commercial SpeB (200nM) and cleavage of AP-PAR-1 reporter construct
was carried out. Thrombin (IIa, 1nM) served as positive control. Experiments were repeated at least 3 times with N=9, data
presented as mean +/- SEM, *P<0.05, **P<0.01.
doi: 10.1371/journal.pone.0081298.g002
Streptococcal SpeB Cleaves PAR-1
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whereas supernatants from speB deficient GAS did not. This
excluded significant cleavage of the reporter construct within
the linker region or the AP molecule (Figure S1).
In order to map the exact cleavage site more precisely we
constructed numerous variants of AP-PAR-1. None of the
mutants known to prevent thrombin-mediated cleavage of
PAR-1 resisted SpeB (Figure 6A). However the AP-PAR-1
variant carrying a long deletion between L44 and W56 was
resistant to cleavage consistent with our previous conclusions
(Figure 5). Shorter deletions narrowed the cleavage site
position to leucine residues 44 and 45 consistent with our data,
showing that ATAP2 (epitope L44 to R46) blocked cleavage.
Reduced base line ERK phosphorylation and blunted
thrombin responses following SpeB
Cleavage at L44/45 had been previously described for the
human protease cathepsin G [34] without elucidating the
biological consequences. We first analysed whether SpeB
affects extracellular-signal-regulated kinases (ERK1/2) in
EA.hy926 endothelial cells via PAR-1. The prototypical
physiological PAR-1 agonist thrombin as well as a synthetic
soluble peptide TFLLR which is homologous to the thrombin-
generated tethered ligand, induced ERK1/2 phosphorylation
whereas SpeB did not (Figure 7A). In cells that had been pre-
incubated with commercial SpeB the base line activity of
ERK1/2 was even slightly decreased as compared to only
buffer treated cells and the thrombin response was blunted. In
contrast commercial SpeB pre-incubation did not affect the
response to TFLLR consistent with (1) no toxic effects of
commercial SpeB and (2) unaffected functionality of PAR-1’s
receptor domain. Pre-stimulation with thrombin as a further
control resulted in an increased base line activity of ERK1/2 but
maintained inducibility by thrombin and TFLLR consistent with
only minor desensitization of PAR-1 by the agonist
concentrations used.
Lack of thrombin induced platelet aggregation
following SpeB incubation
PAR-1 signaling is crucial for platelet activation. We studied
aggregation of washed platelets by turbidimetric analysis to
analyze biological effects of SpeB on PAR-1 in platelets. First,
aggregation in native platelets (without pre-treatment) was
analyzed following exposure to buffer control or thrombin or the
soluble PAR-1 agonist TFLLR or commercial SpeB (Figure 7B).
In accordance with our previous data showing that SpeB did
not induce ERK1/2 (Figure 7A) commercial SpeB also did not
induce platelet aggregation, whereas thrombin and TFLLR
induced aggregation. We then tested whether pre-treatment
with commercial SpeB could influence platelet response to
PAR-1 agonists. Consistent with our ERK1/2 phosphorylation
data, pre-incubation with commercial SpeB blunted effects of
thrombin whereas platelets fully responded to TFLLR
consistent with commercial SpeB rendering the tethered ligand
of PAR-1 dysfunctional but not otherwise affecting platelet
function.
Figure 3.  GAS strains cleaving PAR-1 expressed functional SpeB.  (A) 293T cells transiently expressing alkaline phosphatase
tagged PAR-1 were incubated with overnight supernatants of well characterized clinical GAS isolates M1T1, M49 and new clinical
GAS isolates (Cl1-8). Then AP-PAR-1 cleavage was assessed. Thrombin (IIa; 1nM) served as positive control. (B) Samples from
(A) were analysed for proteolytic SpeB activity by evaluating Bz-Pro-Phe-Arg-Nan cleavage. Experiments were repeated at least 3
times with N=9, data presented as mean+/- SEM.
doi: 10.1371/journal.pone.0081298.g003
Streptococcal SpeB Cleaves PAR-1
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Discussion
We showed that the cysteine protease SpeB, a major GAS
virulence factor, cleaved PAR-1. Our results indicate that SpeB
specifically cleaved human PAR-1, but neither human PAR-2
nor 4. Human PAR-3 was cleaved very inefficiently. We provide
3 lines of evidence that PAR-1 was cleaved at the single amino
acid residue leucine44, a cleavage site previously reported to be
specific for the human protease cathepsin G [34]. We further
found that PAR-1 cleaved at leucin44 rendered human
endothelial cells and platelets unresponsive to their
physiological activator thrombin.
The PAR-1 cleaving protease present in GAS supernatants
was specifically expressed in stationary phase cultures.
Experiments involving inhibitors classified this PAR-1 cleaving
protease to the cysteine protease family. Using a modified
‘molecular’ Koch’s postulate with bacteria engineered to either
express SpeB or not together with complementation
experiments adding exogenous commercial SpeB alone or
together with GAS supernatant from speB-deficient GAS
identified SpeB as the protease directly cleaving PAR-1. On the
host’s side our studies using PAR-1 overexpressing cells were
further confirmed by studies with endogenously PAR-1
expressing endothelial cells. Cell surface ELISA techniques
were used to corroborate that SpeB-PAR-1 cleavage was
neither an artefact due to overexpressing PAR-1 nor due to
specific characteristics of our PAR-1 cleavage reporter
construct.
PAR-1 has been recognized to be a ‘Janus like receptor’
given its ability to mediate divergent biological effects
dependent on what tethered activation ligand was uncovered
through a N-terminal cleavage event [11,13]. Herein we provide
complementary evidence that SpeB cleaves PAR-1 at a novel
cleavage site (leucine44). Overexpressed PAR-1 carrying
deletions and endogenous PAR-1 in conjunction with cleavage
using blocking anti-PAR-1 antibodies were used. To our
knowledge it has so far not been studied whether the tethered
ligand of L44 cleaved PAR-1 activates either its own receptor
body (in cis) or an adjacent PAR 1, 2, 3 or 4 molecule in trans
albeit the fact that the site had already been identified for
human protease cathepsin G [34]. Multiple active states of
PAR1 have been described which depend on whether the
Figure 4.  AP-PAR-1 cleavage efficiency by SpeB and thrombin.  A large concentration range (starting at 10pM up to 29nM) of
commercial SpeB and thrombin (IIa) was analysed for AP-PAR-1 cleavage efficiency. Experiments were repeated at least 3 times
with N=9 per point, data presented as mean+/- SEM, *P<0.05, **P<0.01.
doi: 10.1371/journal.pone.0081298.g004
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Figure 5.  SpeB cleaved endogenous PAR-1 at the ATAP2 epitope and ATAP2 blocked cleavage of overexpressed
PAR-1.  (A) Scheme of PAR-1’s extracellular N-terminus. In bold are given the thrombin and activated protein C cleavage (and
activation) sites shown at arginine41 and arginine46, respectively. Underscores mark the hirudin binding site, the domain directly
binding thrombin’s exosite I. Further monoclonal anti-PAR-1 ATAP2 and WEDE15 epitopes are provided. (B) Following incubation
of endothelial EA.hy926 cells with given agonists, supernatants from GAS or SpeB deficient GAS in the absence or together with
protease inhibitor E64 or SpeB cells were fixed with PFA and epitopes of anti-PAR-1 ATAP2 (white bars) and WEDE15 (black bars)
were quantified by cell surface ELISA. (C) Following incubation with either anti-PAR-1 ATAP2 or WEDE15, 293T cells transiently
over-expressing AP-PAR-1 were assessed for PAR-1 cleavage by GAS supernatant and commercial SpeB. Experiments were
repeated at least 3 times with N=9 per point, data presented as mean+/- SEM, **P<0.01.
doi: 10.1371/journal.pone.0081298.g005
Streptococcal SpeB Cleaves PAR-1
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receptor was cleaved at R41 or R46 [11,13] resulting in PAR1
activation. Either cleavage site generates a specific tethered
ligand that is also specific for biological downstream effects.
We now identified an additional novel L44 cleaved tethered
ligand generated by SpeB. It remains to be clarified whether it
induces a novel active state of PAR1 which would resemble the
R46 cleaved PAR1 or whether the ligand is shed and thus non-
functional. Our data involving studies in a human endothelial
cell line and human platelets suggest SpeB to generate an
ineffective tethered ligand. Whether such activation ligand
destroying (or shedding) effects also blunt PAR-1’s anti-
apoptotic effects and whether such shedding might help to
explain pro-apoptotic effects of SpeB in human monocyte and
lymphocyte like cell lines remains to be clarified [35,36].
SpeB has been shown to be an important GAS virulence
factor. On the one hand, SpeB is recognized as a major
virulence factor in both in vitro and in vivo experiments due to
its capacity to degrade host matrix protein [37], epithelial
junctions [38], immunoglobulin [39–41] and complement
[42,43]. On the other hand, diminished SpeB expression
caused by mutations within the CovR/S two component system
has been linked to invasive GAS strains [3]. Benefits of
abolished SpeB expression were so far explained by reduced
SpeB-mediated degradation of other GAS virulence factors
such as the DNase Sda1. Our observation that SpeB blunts
platelet activation adds an additional dimension to SpeB
pathogenicity. Reduced SpeB expression is beneficial for blood
stream invasion [3] suggesting negative selection of SpeB-
expressing GAS in this compartment. One is thus tempted to
speculate that the lack of platelet activation by SpeB-
expressing GAS within the blood stream might reduce their
virulence. GAS is always coated by fibrinogen [44], a plausible
mechanism could thus be that SpeB-deficient GAS is
preferentially bound to activated platelets promoting micro-
thrombosis resulting in tissue invasion.
In summary cleavage of PAR-1 is a novel function of
streptococcal SpeB. Our results indicate that among the 4
mammalian expressed PARs (1 to 4) SpeB is specific for
PAR-1 and that cleavage occurred at the single amino acid
residue leucine44. SpeB rendered PAR-1 irresponsive for
thrombin in endothelial cells and most importantly rendered
platelets unresponsive to their physiological activator thrombin.
Further studies will be required to explore the importance of
SpeB-cleaved PAR-1 in GAS virulence.
Materials and Methods
Reagents
Clotting proteases were purchased from Haematologic
Technologies (Essex Junction, VT, USA), with the exception of
Trypsin (Gibco; Life technologiesTM Europe, Zug, CH).
Commercial SpeB was purchased from Toxin Technology Inc.
(Sarasota, FL, USA). PAR-1 activating peptides corresponding
to the N-terminus of R41 cleaved PAR-1 (TFLLRNPN) were
custom made (Antagene; Sunnyvale, CA, USA) and used at a
final concentration of 20µM. Protease inhibitors EDTA, PMSF,
benzamidin and E64 were from Sigma-Aldrich Chemie GmbH
(Buchs, CH). Monoclonal anti-PAR-1 ATAP2 and WEDE15
were applied as described previously [11,25,32] and used at
1μg/mL for analytic assays and at 25μg/mL for 10 min in
Figure 6.  SpeB specifically cleaved endogenous PAR-1 at leucine44/45.  GAS supernatant and thrombin (IIa; 1nM) were
analysed for their ability to cleave (A) variants of AP-PAR-1 with alanine substitutions at indicated positions and (B) mutants of AP-
PAR-1 with deletions at indicated positions. Experiments were repeated at least 3 times with N=9 per point, data presented as mean
+/- SEM.
doi: 10.1371/journal.pone.0081298.g006
Streptococcal SpeB Cleaves PAR-1
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cleavage blocking studies. Western blots detecting
phosphorylated ERK1/2 were done with the antibodies p44/42
MAPK (#9101, Cell signalling, Inc.; Cambridge, GB) and goat
anti-rabbit HRP (#7074, Cell signalling, Inc.; Cambridge, GB)
used as described [32], anti-β-actin antibody (Sigma-Aldrich
Chemie GmbH; Buchs, CH) and goat anti-mouse HRP (Life
technologies Europe; Zug, Switzerland) for β-actin detection
and antibodies anti-FLAG M2 (Sigma-Aldrich Chemie GmbH;
Buchs, CH) and goat anti-mouse HRP for detecting FLAG-
tagged AP-PAR-1.
Bacterial strains
The GAS strain 5448, a well-characterized M1T1 clinical
isolate from a patient with necrotizing fasciitis and toxic shock
syndrome [45] was used as well as clinical isolates from the
University Hospital Zurich, Division of Infectious Diseases and
Hospital Epidemiology (Table S1). The GAS strain M1T1
lacking the speB gene (GASM1T1 ΔspeB) [46] was used as a
control for loss of speB function. All GAS strains were grown in
Todd Hewitt Broth (BD; Sparks, MD, USA) supplemented with
0.5% yeast extract (THY) at 37°C under static conditions. Other
pathogenic bacteria such as Pseudomonas aeruginosa were
grown in Luria Bertani Broth (BD; Sparks, MD, USA) at 37°C
with shaking. Culture supernatants were harvested by
centrifugation (4000 rpm, 10 min), filter-sterilized through a
0.22 µm filter (Merck Millipore Ltd.; Cork, IRL), immediately
quick frozen in liquid nitrogen and stored at -20°C. Purified
SpeB was obtained from stationary phase grown GAS
supernatants as described previously [47] and used to
compare enzyme activity to commercial SpeB (Figure S2).
GAS emm typing
emm typing was performed by colony PCR using 5’-
tattcgcttagaaaattaa-3’ (forward primer) and 5’-
gcaagttcttcagcttgttt-3’ (reverse primer) in conjunction with taq
polymerase (Sigma-Aldrich). PCR products were sequenced
and compared to the CDC data base (http://www.cdc.gov/
ncidod/biotech/strep/m-proteingene_typing.htm)
Cell culture and transfection
EA.hy926 cells [48] and 293T cells were obtained from the
American Type Culture Collection (ATCC®, CRL-11268™) were
cultivated and propagated as described previously [32]. For
transient over-expression lipofection was performed using
expression plasmids (pcDNA3.1/Zeo+ and pcDNA3.1/Hygro+;
Life technologies Europe; Zug, Switzerland) and Lipofectamine
2000 (Life technologies Europe; Zug, Switzerland) according to
the manufacture’s instruction. Constructs for tagged and non
tagged PAR’s were made as described [11,25] and the
sequences are provided (Table S2 and Table S3). All
mutations and deletions were obtained by site directed
mutagenesis using the Phusion® Site-Directed Mutagenesis Kit
Figure 7.  SpeB-cleaved PAR-1 silenced ERK1/2 phosphorylation and blunted thrombin-mediated platelet aggregation.  (A)
Following pre-incubation with buffer alone (open bars), commercial SpeB (grey) or thrombin (black) EA.hy926 endothelial cells were
treated with given agonists and assessed by Western blot. β-actin served as loading control. The upper part of the panel provides
quantitative analysis of 4 pooled experiments; one-way-ANOVA yielded P<0.001 overall, P<0.004 for buffer, P<0.001 for speB and
P<0.021 for IIa pre-incubated subgroups. Within each subgroup samples were compared to the corresponding buffer control
(Dunnet’s posthoc comparison) *P<0.05, **P<0.01. The lower part of the panel shows a representative blot with visualized bands for
phosphorylated ERK and β-actin. (B) Washed human platelets were pre-incubated 15 min with buffer alone (open symbols) or
commercial SpeB (closed symbols) before addition of indicated agonists and quantification of aggregation. Representative graph of
3 experiments with N=9, data presented as mean+/- SEM, *P<0.05, **P<0.01.
doi: 10.1371/journal.pone.0081298.g007
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(NEB; Ipswich, MA, USA). All constructs were verified by
sequencing.
PAR-1 cleavage reporter assay
293T cells transiently expressing alkaline phosphatase (AP)-
tagged PAR cleavage reporter constructs (sequences provided
in Table S2 and Table S3), quantification of PAR cleavage and
verification of appropriate reporter construct expression was
done as reported [11,25]. In brief, cells were washed twice and
incubated with pre-warmed agonists (37°C). In all experiments,
except from those shown in Figure 1, the agonists were
supplemented with DTT (final conc. 1mM; Fermentas/Thermo
Scientific; Rockford, IL, USA). Following the agonist incubation
of 20 min, supernatants from PAR reporter constructs
expressing 293T cells were removed, separated from cell
debris by passing them through a cellulose ester membrane
(pore size, 0.45 µm; Millipore, Bedford, MA, USA). AP activity
was quantified by incubation with the colorimetric substrate p-
nitrophenyl phosphate (1-Step PNPP; Thermo Scientific,
Rockford, IL, USA) for around 10 min before endpoint
measurements with the Labsystems Multiskan MCC/340 plate
reader (Thermo Scientific, Rockford, IL, USA).
In all experiments buffer controls were subtracted and used
as base line.
Cell surface immunoassays and Western blotting
Endothelial EA.hy926 cell surface PAR-1 was quantified by
cell surface enzyme-linked immunosorbent assay as described
previously[11,25,32]. In brief following agonist incubation cells
were PFA (2%) fixed, probed with detection antibody, followed
by incubation with HRP-labelled goat-anti mouse antibody and
colorimetric quantification using the HRP substrate 3,3',5,5'-
Tetramethylbenzidine (Thermo Scientific, Rockford, IL, USA).
Western blotting was performed as described [32] and
antibodies used are provided within the reagent section. In brief
proteins were extracted using 2x sample buffer at 80°C, after
sonication samples were then separated by SDS-PAGE under
reducing conditions, transferred to nitrocellulose (Thermo
Scientific, Rockford, IL, USA), blocked, and probed with
detection antibody at 1μg/mL followed by HRP-coupled
secondary antibody and visualization using the SuperSignal
West Femto detection system (Thermo Scientific, Rockford, IL,
USA). Optical density of both immunoreactive bands of protein
of interest and β-actin for loading control was assessed using
the Alpha Innotech FluorChemQ system and the Alpha view
software version 2.0.1.1 (Alpha Innotech/Protein simple, Santa
Clara, CA, USA).
Quantification of SpeB enzyme activity
SpeB was quantified in accordance to [28]. Twenty µl of
overnight supernatants were mixed with 110 µl of PBS and 10
µl of DTT (final concentration 1mM). After incubation (37°C, 30
min) 20 µl of 2.6mM Bz-Pro-Phe-Arg-Nan (Sigma-Aldrich
Chemie GmbH; Buchs, CH) were added and the increase in
absorbance at 405 nm was quantified by a kinetic plate reader
(BioTek Synergy HT, BioTek Instruments GmbH; Luzern,
Switzerland). The maximal slope of the curve was calculated
and used to quantify SpeB activity. Commercial SpeB protein
(13.3 µg/ml, ToxinTechnology, USA) and THY were used as
positive and negative controls, respectively.
Analysis of soluble N-terminal PAR-1 peptide by mass
spectrometry
A soluble PAR-1 peptide covering amino acid 37-64 with an
N-terminal biotin-tag and a C-terminal His-tag (ProteoGenix;
Schiltigheim, F) was bound to Dynabeads M-280 Streptavidin
(Life technologies Europe; Zug, CH) as described in the
manufacturer’s instruction. After washing off unbound peptide,
beads were incubated with 20 µl GAS M1T1 supernatant or
400 pmol commercial SpeB supplemented with 1mM DTT for
30 min at 37°C. Cleaved (released) C-terminal peptide
fragment was then captured with His-Tag Isolation & Pulldown
dynabeads (Life technologies Europe; Zug, CH) and eluted as
described in the manual followed by analysis by MALDI/MS/MS
(Functional Genomic Centre University/ETH Zürich,
Switzerland).
Platelet aggregation assay
Blood was drawn according to the protocol 2010-0126/0
which was approved by the Institutional Review Board of the
University of Zurich, Zurich Switzerland, and after written
informed consent was obtained from all participants. Citrate
blood was supplemented with 7.4 ng/mL Prostine VR (Pfizer
AG; Zurich, CH), centrifuged 15 min at 135×g; platelet-rich
plasma was removed and layered on Histopaque1119 (Sigma-
Aldrich Chemie GmbH; Buchs, CH) and 20% human albumin
(CSL Behring, Bern, CH). Platelets were further purified by
centrifugation (10 min at 100×g) followed by a second
centrifugation step (35 min 800×g). The intermediate platelet
layer was then diluted with modified Hepes-tyrods buffer (1:1;
134mM NaCl, 12mM NaHCO3, 5mM glucose, 10mM Hepes,
0.34mM NaH2PO4,pH7.4) and supplemented with 5mM CaCl2,
1mM MgCl2. Platelets were pre-incubated with Hepes-tyrods
buffer or commercial SpeB (endconc. 200nM) in a FCS (Life
technologies Europe; Zug, CH) coated 96 well plate (Nunc,
immune plates polysorb C96; Thermo Scientific; Rockford, IL,
USA) for 15 min at 37°C with shaking. Aggregation was then
analysed immediately after addition of agonists by kinetic
determination of the absorbance at 595nm while keeping the
plate at 37°C shaking (modified from Armstrong PCJ 2009
[49]).
Statistics
Data analysis and presentation was performed using NCSS,
SPSS software packages. A two-sample, two-tailed
homoscedastic t-test was used to calculate the indicated P-
values. Where indicated one-way-ANOVA with Dunnett’s post
hoc comparison to the control sample was used. In PAR-
cleavage reporter, ELISA and colorimetric assays buffer control
samples were subtracted as background P-values for platelet
aggregation over time was estimated using log rank.
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Supporting Information
Figure S1.  No cleavage of AP-PAR-1 construct outside
PAR-1’s N-terminus. 293T cells transiently expressing
alkaline phosphatase and FLAG-tagged PAR-1 were incubated
with bacterial supernatants, thrombin (IIa; 1nM) or buffer.
Supernatants and cells were then separately analysed by
Western blot for N-terminal PAR-1 cleavage. Representative
experiment out of 3.
(TIF)
Figure S2.  SpeB column purified from GAS supernatants
and commercial SpeB cleaved PAR-1 with comparable
efficiency. 293T cells transiently expressing alkaline
phosphatase-tagged PAR-1 were incubated with indicated
amounts of column purified (pSpeB) and commercial SpeB and
cleavage of PAR-1 reporter constructs was quantified.
Thrombin (IIa; 1nM) served as a positive control.
(TIF)
Table S1.  Characteristics of GAS clinical isolates.
(TIFF)
Table S2.  Amino acid sequences of PAR reporter
constructs.
(TIFF)
Table S3.  Amino acid sequences encoding mutants of
PAR1 reporter construct.
(TIFF)
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